8-K: Coda Octopus Group Appoints New CFO
Current Report (8-K)
Coda Octopus Group, Inc. announced the appointment of Mark Kelly as Chief Financial Officer, effective August 3, 2026, succeeding interim CFO Gayle Jardine.
Summary
- Coda Octopus Group, Inc. has appointed Mark Kelly as its new Chief Financial Officer (CFO).
- The appointment is effective August 3, 2026, and is subject to a three-month probationary period that may be extended.
- Gayle Jardine, the current Interim CFO, will retire on August 3, 2026.
- Mark Kelly's prior experience includes roles as Finance Director at Medac Pharma, Head of Glasgow Finance at Chubb Insurance, Finance Director at Twist Bioscience Corp., and Senior Finance Director/European Controller at Charles River Laboratories.
- He qualified as a Chartered Accountant in 1996 and holds a BA Honours in Accounting and Finance from the University of Strathclyde.
- Mr. Kelly will receive an annual base salary of £165,000 (approximately $218,625).
- He is eligible for discretionary annual bonuses and will receive a restricted stock grant valued at $40,000, vesting in two equal annual installments starting October 31, 2027, contingent on performance milestones.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the structured and experienced appointment of a new CFO, balanced by the standard probationary and performance-based vesting conditions.
Positives
- Appointment of a new CFO with extensive financial experience in various sectors, including pharmaceuticals, insurance, synthetic DNA, and life sciences contract research.
- The new CFO, Mark Kelly, is a qualified Chartered Accountant with a strong educational background.
- A restricted stock grant is included, aligning the new CFO's interests with long-term company performance and shareholder value.
- The base salary is clearly defined, providing transparency regarding compensation.
Negatives
- The appointment is subject to a three-month probationary period, with a potential two-month extension, indicating a cautious approach by the company.
- Vesting of the restricted stock grant is tied to performance milestones, which introduces uncertainty regarding the full realization of the equity award.
Risks
- The transition of the Chief Financial Officer role could present a temporary period of adjustment for financial operations.
- The effectiveness of the new CFO in meeting performance milestones for stock vesting remains to be seen.
Future Outlook
The company has appointed a new Chief Financial Officer, Mark Kelly, who will assume his role on August 3, 2026. His compensation package includes a base salary, potential bonuses, and a restricted stock grant that vests over two years and is subject to performance milestones, indicating a focus on long-term value creation and performance.
Management Comments
- Gayle Jardine, Interim Chief Financial Officer of Coda Octopus Group, Inc. (the Company), will retire from her position effective August 3, 2026. As a result of her retirement, the Company will appoint a new Chief Financial Officer.
- On July 1, 2026, the Company finalized the appointment of Mark Kelly to be the Chief Financial Officer, effective August 3, 2026, subject to a three-month probationary period which, at the discretion of the Company, may be extended by an additional two months.
Industry Context
StockSavvy.ai notes that the appointment of a new Chief Financial Officer is a common event, especially following an interim period. The detailed background of Mark Kelly, with experience in diverse industries like pharmaceuticals and life sciences, suggests the company is seeking robust financial leadership. The inclusion of performance-based equity aligns with current best practices in executive compensation to drive shareholder value.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | Gayle Jardine (Interim) | Mark Kelly | 2026-08-03 | Retirement of interim CFO |
Stakeholder Impact
- Shareholders: The appointment of a new CFO with a performance-linked compensation package is intended to align executive interests with shareholder value creation.
- Employees: The transition in leadership may lead to adjustments in financial reporting and strategic financial planning.
- Management: The new CFO will be responsible for overseeing the company's financial operations and strategy.
Next Steps
- Mark Kelly to commence his role as Chief Financial Officer on August 3, 2026.
- The company will monitor Mark Kelly's performance during the three-month probationary period, with the option to extend it by two months.
- The restricted stock grant will begin vesting on October 31, 2027, subject to performance milestones.
Key Dates
| Date | Description |
|---|---|
| 2024-01-01 | Start of Mark Kelly's tenure as Finance Director at Medac Pharma (assumed start date based on 'From 2024 until 2025') |
| 2025-12-31 | End of Mark Kelly's tenure as Finance Director at Medac Pharma (assumed end date based on 'From 2024 until 2025') |
| 2016-01-01 | Start of Mark Kelly's tenure as Senior Finance Director and European Controller at Charles River Laboratories (assumed start date based on 'from 2016 to 2021') |
| 2021-12-31 | End of Mark Kelly's tenure as Senior Finance Director and European Controller at Charles River Laboratories (assumed end date based on 'from 2016 to 2021') |
| 2021-01-01 | Start of Mark Kelly's tenure as Finance Director at Twist Bioscience Corp. (assumed start date based on 'From 2021 to 2022') |
| 2022-12-31 | End of Mark Kelly's tenure as Finance Director at Twist Bioscience Corp. (assumed end date based on 'From 2021 to 2022') |
| 2022-01-01 | Start of Mark Kelly's tenure as Head of Glasgow Finance at Chubb Insurance (assumed start date based on 'From 2022 to 2024') |
| 2024-12-31 | End of Mark Kelly's tenure as Head of Glasgow Finance at Chubb Insurance (assumed end date based on 'From 2022 to 2024') |
| 1996-01-01 | Mark Kelly qualified as a Chartered Accountant. |
| 2026-07-01 | Date of the earliest event reported in the Form 8-K filing. |
| 2026-07-01 | Date of the Form 8-K filing. |
| 2026-08-03 | Effective date of Mark Kelly's appointment as Chief Financial Officer and retirement date of Gayle Jardine. |
| 2027-10-31 | Commencement date for the first installment of the restricted stock grant vesting. |
Keywords
Coda Octopus Group, Form 8-K, Chief Financial Officer, CFO Appointment, Mark Kelly, Gayle Jardine, Executive Transition, Securities and Exchange Commission, Corporate Finance, Personnel Change
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.